Therefore, pharmacological treatment of hypertriglycer- idemia is not recommended in children with CKD. This is a weak recommendation that reflects the lack of evidence on clinical benefit and safety. Treatment could be considered in children with very severely increased hypertriglyceridemia (411.3 mmol/l [41000 mg/dl]); such children should be referred to a pediatric lipid specialist for management and to rule out familial hypertriglyceridemia or rare, inherited disorders such as lipoprotein lipase deficiency or apolipo- protein C-II deficiency. Suggested Audit Criteria K Audit the number of pediatric CKD patients treated with TLC, diet, and weight loss for lowering TGs. K Audit the number of pediatric CKD patients treated with pharmacological TG-lowering therapy. K Record the number of pediatric CKD patients with drug intolerance and/or non-compliance. KEY POINTS K TLC should be recommended to children with CKD and hypertriglyceridemia. K Fibric acid derivatives are not recommended to prevent pancreatitis or reduce cardiovascular risk in children with CKD and hypertriglyceridemia. RESEARCH RECOMMENDATIONS Future studies should be conducted to: K Determine prevalence of hypertriglyceridemia in pediatric kidney transplant recipients. K Determine the effect of diet and weight loss in lowering TG among pediatric CKD patients. DISCLAIMER While every effort is made by the publishers, editorial board, and ISN to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, copyright holder, or advertiser concerned. Accordingly, the publishers and the ISN, the editorial board and their respective employers, office and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. 